Jefferies analyst Kelly Shi raised the firm’s price target on PTC Therapeutics (PTCT) to $77 from $63 and keeps a Buy rating on the shares. After having surveyed 20 experienced and high-volume U.S.-based doctors for PKU to assess the current treatment algorithm and their enthusiasm and willingness to prescribe Sephience, the firm is raising its Sephience peak sales estimate on higher penetration expectations, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTCT Upcoming Earnings Report: What to Expect?
- PTC Therapeutics price target raised to $87 from $76 at BofA
- Optimistic Buy Rating for PTC Therapeutics Driven by Strong Demand and Promising Sales Projections for Sephience
- Strong Buy Rating for PTC Therapeutics Driven by Sephience Launch and Strategic Growth Opportunities
- Citizens JMP healthcare analysts hold an analyst/industry conference call